Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology
Authors:
Open Access
- 1 October 2017
- journal article
- Published by Elsevier in European Urology
- Vol. 72 (4) , 509-518
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trialThe Lancet Oncology, 2015
- More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate CancerEuropean Urology, 2015
- Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate CancerJournal of Clinical Oncology, 2015
- Radical Prostatectomy or Watchful Waiting in Early Prostate CancerNew England Journal of Medicine, 2014
- Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)The Lancet, 2012
- Radical Prostatectomy versus Observation for Localized Prostate CancerNew England Journal of Medicine, 2012
- The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary ManagementJournal of Clinical Oncology, 2004
- Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413Journal of Clinical Oncology, 2003
- Is a Limited Lymph Node Dissection An Adequate Staging Procedure for Prostate Cancer?Journal of Urology, 2002